)
)
Egetis Therapeutics Investor Relations Material
Latest events
Q3 2024
Egetis Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Egetis Therapeutics
Access all reports
Egetis Therapeutics develops and markets drugs for the treatment of rare and serious diseases in the orphan drug segment. Its main drug candidates currently include Aladote, a drug that reduces the risk of acute liver injury associated with acetaminophen/paracetamol poisoning and is being developed in phase IIb/III clinical trials; and Emcitate, a drug for the treatment of MCT8 deficiency (a rare inborn error of thyroid hormone signaling).
Key slides for Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
EGTX
Country
🇸🇪 Sweden